UA103158C2 - Конъюгат белок-полимер и способ лечения с его помощью - Google Patents

Конъюгат белок-полимер и способ лечения с его помощью

Info

Publication number
UA103158C2
UA103158C2 UAA201002978A UAA201002978A UA103158C2 UA 103158 C2 UA103158 C2 UA 103158C2 UA A201002978 A UAA201002978 A UA A201002978A UA A201002978 A UAA201002978 A UA A201002978A UA 103158 C2 UA103158 C2 UA 103158C2
Authority
UA
Ukraine
Prior art keywords
protein
polymer conjugate
treating method
hepatitis
virus
Prior art date
Application number
UAA201002978A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ко-Чун Линь
Original Assignee
Фармаиссеншиа Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA103158(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармаиссеншиа Корп. filed Critical Фармаиссеншиа Корп.
Publication of UA103158C2 publication Critical patent/UA103158C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение касается конъюгатов белок-полимер, раскрытых в описании. Кроме того, описанный способ получения конъюгата белок-полимер и его применение для лечения инфекции вируса гепатита С или вируса гепатита В.
UAA201002978A 2007-08-16 2008-08-15 Конъюгат белок-полимер и способ лечения с его помощью UA103158C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (en) 2007-08-16 2008-08-15 Protein-polymer conjugates

Publications (1)

Publication Number Publication Date
UA103158C2 true UA103158C2 (ru) 2013-09-25

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002978A UA103158C2 (ru) 2007-08-16 2008-08-15 Конъюгат белок-полимер и способ лечения с его помощью

Country Status (31)

Country Link
US (1) US8143214B2 (ru)
EP (2) EP4129343A1 (ru)
JP (1) JP5613050B2 (ru)
KR (1) KR101588465B1 (ru)
CN (1) CN101367872B (ru)
AR (1) AR067964A1 (ru)
AU (1) AU2008286742B2 (ru)
BR (1) BRPI0814482B8 (ru)
CA (1) CA2696478C (ru)
CL (1) CL2008002399A1 (ru)
CY (2) CY1125751T1 (ru)
DK (1) DK2205281T3 (ru)
EA (1) EA018111B1 (ru)
ES (1) ES2924727T3 (ru)
FR (1) FR22C1045I2 (ru)
HR (1) HRP20220937T3 (ru)
HU (2) HUE059551T2 (ru)
LT (1) LT2205281T (ru)
LU (1) LUC00277I2 (ru)
MX (1) MX2010001750A (ru)
MY (1) MY149148A (ru)
NL (1) NL301195I2 (ru)
NO (1) NO2022038I1 (ru)
NZ (1) NZ583831A (ru)
PL (1) PL2205281T3 (ru)
PT (1) PT2205281T (ru)
SI (1) SI2205281T1 (ru)
TW (1) TWI381851B (ru)
UA (1) UA103158C2 (ru)
WO (1) WO2009023826A1 (ru)
ZA (1) ZA201001777B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
CA2964390A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用
WO2025254932A1 (en) * 2024-06-03 2025-12-11 Pharmaessentia Corporation Selective treg stimulator and methods of uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO2001015736A2 (en) * 1999-08-27 2001-03-08 Maxygen Aps Interferon-beta conjugates
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
ES2725808T3 (es) * 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
US7405198B2 (en) * 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
JP2008511610A (ja) 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CA2698173C (en) 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
CN101636411B (zh) 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2a及其制备方法和应用
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
US8143214B2 (en) 2012-03-27
DK2205281T3 (da) 2022-08-15
FR22C1045I1 (fr) 2022-10-14
EA201070282A1 (ru) 2010-08-30
AU2008286742B2 (en) 2014-05-29
KR20100076945A (ko) 2010-07-06
EP2205281B1 (en) 2022-06-29
SI2205281T1 (sl) 2022-11-30
KR101588465B1 (ko) 2016-01-25
PL2205281T3 (pl) 2022-12-12
BRPI0814482A2 (pt) 2015-02-03
HRP20220937T3 (hr) 2022-09-30
EP2205281A4 (en) 2014-10-08
EP2205281A1 (en) 2010-07-14
ES2924727T3 (es) 2022-10-10
NL301195I2 (nl) 2023-03-02
HUS2200039I1 (hu) 2022-09-28
PT2205281T (pt) 2022-08-02
NZ583831A (en) 2012-06-29
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
JP5613050B2 (ja) 2014-10-22
CY1125751T1 (el) 2023-06-09
NL301195I1 (ru) 2022-08-31
LT2205281T (lt) 2022-09-26
LUC00277I2 (ru) 2025-05-12
WO2009023826A1 (en) 2009-02-19
HUE059551T2 (hu) 2022-11-28
US20090053177A1 (en) 2009-02-26
EA018111B1 (ru) 2013-05-30
CN101367872B (zh) 2013-11-20
CL2008002399A1 (es) 2009-01-02
CN101367872A (zh) 2009-02-18
MX2010001750A (es) 2010-06-01
EP4129343A1 (en) 2023-02-08
AR067964A1 (es) 2009-10-28
AU2008286742A1 (en) 2009-02-19
ZA201001777B (en) 2010-12-29
BRPI0814482B1 (pt) 2021-02-02
CA2696478C (en) 2018-10-09
TW200916116A (en) 2009-04-16
FR22C1045I2 (fr) 2023-12-29
JP2010536788A (ja) 2010-12-02
BRPI0814482B8 (pt) 2021-05-25
CY2022026I2 (el) 2023-06-09
CY2022026I1 (el) 2023-06-09
NO2022038I1 (no) 2022-09-02
CA2696478A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1117641T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201100390A1 (ru) Соединения для лечения гепатита с
EA200700243A1 (ru) Способы лечения гепатита с
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2010047830A3 (en) Agents for hcv treatment
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
SG179488A1 (en) Virus like particle purification
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
ATE547103T1 (de) Hemmer des hepatitis-c-virus
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
EA201200890A1 (ru) Комбинированная терапия hcv
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
UA102414C2 (ru) Циклоундекадепсипептидные соединения для лечения инфекций, вызванных вирусом гепатита с
NO20054494L (no) Peptidvektorer
MX2009005026A (es) Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.